Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children
← catalyst calendarSponsored by DBV Technologies (industry) · DBV.PA — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
304actual
Sites
26
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-12-06 | actual | When the study began enrolling |
| Primary completion | 2025-05-13 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-13 | actual | The whole study's end, after follow-up |
| First posted | 2019-03-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Peanut Allergy
Intervention
- Biological: DBV712 250 mcg
Primary outcomes
what the primary-completion date above is the date OFProportion of subjects reaching an ED ≥1000 mg
measured 12 months
Proportion of subjects reaching an ED ≥1000 mg
measured 24 months
Proportion of subjects reaching an ED ≥1000 mg
measured 36 months
Publications
- PMID 39956162 — linked by the registry
- PMID 37163622 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · DBV.PA's whole pipeline · Catalyst calendar · Every registered study · What changed